Core Insights - Aligos Therapeutics reported significant business progress and financial results for Q4 and full year 2024, highlighting advancements in their clinical pipeline and financial activities [1][2]. Recent Business Progress - The company is advancing ALG-000184 towards a Phase 2 clinical study expected to begin in mid-2025, with the potential to replace standard care for chronic hepatitis B virus infection [2][3]. - ALG-055009 demonstrated statistically significant reductions in liver fat in a Phase 2a study, with up to 70% of subjects achieving a ≥30% relative reduction in liver fat compared to baseline [5][15]. - The company completed a 56.9 million, down from 82.2 million, compared to a net loss of (13.08) [8][20]. - For the full year 2024, the net loss was 87.7 million in 2023, with a basic and diluted net loss per share of (20.94) [9][20]. Research and Development Expenses - R&D expenses for Q4 2024 were 16.0 million, down from 22.3 million in Q4 2023, primarily due to decreased third-party expenses for clinical trials [10]. - For the full year 2024, R&D expenses totaled 70.3 million, slightly down from 73.0 million in 2023, with reductions in employee-related costs offset by increases in third-party expenses [11]. General and Administrative Expenses - G&A expenses for Q4 2024 were 5.2 million, down from 6.4 million in Q4 2023, attributed to decreased third-party expenses [12]. - For the full year 2024, G&A expenses were 22.8 million, compared to $30.6 million in 2023, reflecting a reduction in legal and other third-party expenses [13].
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results